Guardant360 CDx provides complete genotyping in advanced colorectal cancer for guideline-recommended biomarkers, including MSI, expanded KRAS/NRAS and BRAF.
Why is this information important?
A recent study* showed that only 40% of advanced colon cancer patients received guideline-recommended testing to help determine therapy options.